Liquid biopsy accelerates precision medicine
- PMID: 36804455
- DOI: 10.1016/j.annonc.2023.02.004
Liquid biopsy accelerates precision medicine
Conflict of interest statement
Disclosure PA: consultant or advisory role (honoraria): Boehringer Ingelheim, Macrogenics, Roche, Novartis, Amcure, Servier, G1 Therapeutics, Radius, Deloitte, Menarini, Synthon, Amgen, Novartis, Gilead, Lilly; travel grants: Amgen, MSD, Pfizer, Roche, Daiichi Sankyo; research funding to my institution: Roche; stock ownership: none. MI: consultant or advisory role (honoraria): Novartis, Seattle Genetics; travel grants: Gilead, Roche; research grants to my institute: Roche, Pfizer, Natera Inc, Inivata Inc.; stock ownership: none. OA has declared no conflicts of interest.
Comment on
-
Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study.Ann Oncol. 2023 Apr;34(4):389-396. doi: 10.1016/j.annonc.2023.01.008. Epub 2023 Jan 25. Ann Oncol. 2023. PMID: 36709039
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources